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Summary
Background Myeloablative chemoradiotherapy and immunomagnetically purged autologous bone marrow 
transplantation has been shown to improve outcome for patients with high-risk neuroblastoma. Currently, peripheral 
blood stem cells (PBSC) are infused after myeloablative therapy, but the eﬀ ect of purging is unknown. We did a 
randomised study of tumour-selective PBSC purging in stem-cell transplantation for patients with high-risk 
neuroblastoma.
Methods Between March 16, 2001, and Feb 24, 2006, children and young adults (<30 years) with high-risk 
neuroblastoma were randomly assigned at diagnosis by a web-based system (in a 1:1 ratio) to receive either non-
purged or immunomagnetically purged PBSC. Randomisation was done in blocks stratiﬁ ed by International 
Neuroblastoma Staging System stage, age, MYCN status, and International Neuroblastoma Pathology classiﬁ cation. 
Patients and treating physicians were not masked to treatment assignment. All patients were treated with six cycles of 
induction chemotherapy, myeloablative consolidation, and radiation therapy to the primary tumour site plus meta-
iodobenzylguanidine avid metastases present before myeloablative therapy, followed by oral isotretinoin. PBSC 
collection was done after two induction cycles. For purging, PBSC were mixed with carbonyl iron and phagocytic cells 
removed with samarium cobalt magnets. Remaining cells were mixed with immunomagnetic beads prepared with 
ﬁ ve monoclonal antibodies targeting neuroblastoma cell surface antigens and attached cells were removed using 
samarium cobalt magnets. Patients underwent autologous stem-cell transplantation with PBSC as randomly assigned 
after six cycles of induction therapy. The primary endpoint was event-free survival and was analysed by intention-to-
treat. The trial is registered with ClinicalTrials.gov, number NCT00004188.
Findings 495 patients were enrolled, of whom 486 were randomly assigned to treatment: 243 patients to receive non-
purged PBSC and 243 to received purged PBSC. PBSC were collected from 229 patients from the purged group and 
236 patients from the non-purged group, and 180 patients from the purged group and 192 from the non-purged 
group received transplant. 5-year event-free survival was 40% (95% CI 33–46) in the purged group versus 36% (30–42) 
in the non-purged group (p=0·77); 5-year overall survival was 50% (95% CI 43–56) in the purged group compared 
with 51% (44–57) in the non-purged group (p=0·81). Toxic deaths occurred in 15 patients during induction (eight in 
the purged group and seven in the non-purged group) and 12 during consolidation (eight in the purged group and 
four in the non-purged group). The most common adverse event reported was grade 3 or worse stomatitis during 
both induction (87 of 242 patients in the purged group and 93 of 243 patients in the non-purged group) and 
consolidation (131 of 177 in the purged group vs 145 of 191 in the non-purged group). Serious adverse events during 
induction were grade 3 or higher decreased cardiac function (four of 242 in the purged group and ﬁ ve of 243 in the 
non-purged group) and elevated creatinine (ﬁ ve of 242 in the purged group and six of 243 non-purged group) and 
during consolidation were sinusoidal obstructive syndrome (12 of 177 in the purged group and 17 of 191 in the non-
purged group), acute vascular leak (11 of 177 in the purged group and nine of 191 in the non-purged group), and 
decreased cardiac function (one of 177 in the purged group and four of 191 in the non-purged group).
Interpretation Immunomagnetic purging of PBSC for autologous stem-cell transplantation did not improve outcome, 
perhaps because of incomplete purging or residual tumour in patients. Non-purged PBSC are acceptable for support 
of myeloablative therapy of high-risk neuroblastoma.
Funding National Cancer Institute and Alex’s Lemonade Stand Foundation.
Introduction
High-risk neuroblastoma has a high rate of recurrence, 
most commonly in bone and bone marrow.1 Results from 
the Children’s Cancer Group (CCG)-3891 trial2 showed 
that myeloablative chemotherapy with rescue with 
immunomagnetic bead purged autologous bone marrow 
improved outcome compared with conventional dose 
chemotherapy. Immunocytology can detect neuroblastoma 
tumour cells in the bone marrow.3 Genetically labelled 
neuroblastoma cells infused from non-purged bone 
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marrow can contribute to relapse after myeloablative 
therapy.4 These data supported immunomagnetically 
purging bone marrow to remove tumour detectable by 
immunocytology, which has a sensitivity of one tumour 
cell in 10⁵ normal cells.3
Currently, autologous peripheral blood stem cells 
(PBSC) are used to restore haemopoiesis after 
myeloablative therapy for high-risk neuroblastoma. 
Blood has no or fewer neuroblastoma cells detectable by 
immunocytology even when bone marrow is positive.5 
Quantitative real-time PCR (QrtPCR) can detect 
neuroblastoma mRNA in PBSC,6–8 although the eﬀ ect of 
infusing these PBSC has not been deﬁ ned. We postulated 
that immunomagnetic bead purging would decrease 
tumour burden in PBSC and improve outcome. We 
report the results of the randomised Children’s Oncology 
Group (COG) A3973 trial, which compared outcomes for 
high-risk neuroblastoma patients who received 
autologous purged versus non-purged PBSC after 
myeloablative chemotherapy. To our knowledge, this is 
the ﬁ rst randomised study in any cancer to evaluate the 
eﬀ ect of tumour-selective PBSC purging.
Methods
Study design and participants
This phase 3 trial was open from Feb 9, 2001, to March 31, 
2006, for children with high-risk neuroblastoma. Patients 
or parents or guardians provided written informed 
consent according to National Cancer Institute and local 
institutional review board guidelines.
Patients were enrolled from 95 COG member 
institutions in the USA (420) and Canada (66). Eligible 
patients had high-risk neuroblastoma according to the 
Children’s Oncology Group (COG) criteria, including 
previously untreated neuroblastoma in patients younger 
than 1 year with International Neuroblastoma Staging 
System9 (INSS) stage 3, 4, or 4S MYCN ampliﬁ ed 
tumours and, in children aged 1 year or older, stage 4 
tumours, stage 3 tumours with either unfavourable 
histology or MYCN ampliﬁ cation, stage 2 tumours with 
unfavourable histology and MYCN ampliﬁ cation, and 
initially low-risk patients treated with surgery only who 
later progressed with metastatic disease.9 We excluded 
patients aged 12–18 months with stage 4 MYCN non-
ampliﬁ ed tumours and favourable histology, and 
hyperdiploid tumours after an amendment in May, 
2004.10 Additional eligibility criteria included age up to 30 
years, no previous history of chemotherapy, registration 
on companion biology study, ability to tolerate PBSC 
collection, and adequate cardiac, liver, and renal function. 
Randomisation and masking
Patients were randomly assigned to treatment at study 
enrolment using the COG’s online remote data entry 
system, which assigned treatment group in real-time 
based on the balance existing at that time, within blocks 
of size four. The method was random until such time as 
a random assignment exceeded the prespeciﬁ ed margin 
of two within a block, and only then did the method 
become deterministic. Patients were randomly assigned 
(ratio 1:1) to receive either purged PBSC or non-purged 
PBSC at study entry; patients and treating physicians 
were not masked to this assignment. Randomisation was 
stratiﬁ ed into blocks by International Neuroblastoma 
Staging System (INSS) stage,9 age at diagnosis (<365 days 
or ≥365 days), MYCN gene status (ampliﬁ ed or non-
ampliﬁ ed), and International Neuroblastoma Pathology 
Classiﬁ cation (INPC; unfavourable or favourable).11
Procedures
All patients were prescribed identical chemotherapy, 
radiotherapy, and post-myeloablative isotretinoin (ﬁ gure 1). 
Patients without progressive disease and adequate organ 
function received myeloablative carboplatin, etoposide, and 
melphalan,12 with dose adjustment for glomerular ﬁ ltration 
rate (GFR) lower than 100 mL/min per 1·73 m².13 After local 
irradiation, patients could enrol in the COG ANBL0032 trial 
of isotretinoin plus chimeric anti-GD2 monoclonal 
antibody ch14.18, interleukin 2, and GM-CSF versus 
isotretinoin alone,14 with randomisation stratiﬁ ed by 
assigned arm of this study. We assessed response using the 
International Neuroblastoma Response Criteria.9 
We graded adverse events using the National Cancer 
Institute’s Common Toxicity Criteria, version 2.15 Reporting 
was required for all grade 3–5 toxic eﬀ ects (non-targeted). 
To monitor safety during the study, the protocol required 
reporting of all grades of speciﬁ c organ function and 
infectious toxic eﬀ ects (targeted).
PBSC were collected after two induction cycles 
regardless of histological tumour content in the bone 
marrow. Requirements to proceed to consolidation were: 
immunocytology-negative PBSC with minimum of 
1·5×10⁶ CD34 cells per kg for non-purged PBSC or 
minimum of 1×10⁶ viable CD34 cells per kg for purged 
PBSC. We determined viability on a thawed purged 
PBSC aliquot using trypan blue.16 Patients with 
insuﬃ  cient purged PBSC could receive non-purged 
PBSC (or purged bone marrow if non-purged PBSC also 
insuﬃ  cient) meeting protocol criteria. Patients with 
immunocytology-positive non-purged PBSC could be 
recollected and purged. Purged PBSC were shipped 
frozen to the transplant institution and thawed 
immediately before reinfusion. We deﬁ ned neutrophil 
engraftment as the ﬁ rst of three consecutive absolute 
neutrophil counts of more than 500 cells per μL; and 
platelet engraftment as the ﬁ rst of three consecutive 
platelet counts of more than 20 000 without transfusion.
Non-purged PBSC were cryopreserved at collecting 
sites. For purged PBSC, heparinised PBSC were 
transported overnight at ambient temperature to a 
centralised laboratory and purged the day after 
leukapheresis according to US Food and Drug 
Administration (FDA) IDE# BB-IDE 2259. PBSC were 
mixed with 200–300 mg of carbonyl iron per 10⁶ total 
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cells to remove phagocytic cells and decrease the number 
of immunomagnetic beads required. Carbonyl iron and 
attached cells were removed using samarium cobalt 
magnets. Remaining cells were mixed with 
immunomagnetic beads using ﬁ ve monoclonal 
antibodies targeting neuroblastoma cell surface antigens 
(459, HSAN 1·2, BA-1, HNK-1, and 126-4; appendix). 
Magnetic beads and attached cells were removed using 
samarium cobalt magnets.16 Purged samples were 
suspended in L15 containing human serum albumin 
10% volume/volume (Central Lab, Blood transfusion 
Service, Swiss Red Cross, Bern, Switzerland), hetastarch 
1·5% weight/volume, and DMSO 10% volume/volume 
(Cryoserv, Ben Venue Laboratories Inc, Bedford, OH, 
USA) in Cryocyte Freezing bags (Baxter-Fenwal, 
Deerﬁ eld, NJ, USA). Stem-cell samples were also 
cryopreserved in 2 mL Cryovials (Baxter-Fenwal). All 
products were frozen with a rate-controlled programmed 
freezer (Cryomed) to –80°C and stored in liquid nitrogen 
vapour (150°C). Quality control of purged product 
required for release included immunocytology to detect 
neuroblastoma, CD34 viable content on post-purge test 
thaw sample, and endotoxin testing. Cryopreserved 
products were shipped to transplant centres in MVE 
LN2 dry shippers with constant temperature monitoring 
by overnight air delivery.
To detect neuroblastoma cells in PBSC, immuno cytology 
and TLDA assays were done on a PBSC aliquot from day 
1 of leukapheresis on all patients before purging. 
Immunocytology after purging was done with 
mononuclear cells isolated by separation with Ficoll-
Hypaque density media. Immunocytology used mono-
clonal antibodies against cell surface antigens (126-4, 390, 
459, HSAN1·2, and BW575).17,18 The TLDA assay quantiﬁ ed 
CHGA, DCX, DDC, PHOX2B, and TH mRNA expression. 
We deemed results to be detectable if one or more of the 
ﬁ ve genes had a cycle threshold (CT) value lower than 
40 and to be undetectable if no signal was detected for any 
genes after 40 cycles (CT=40). We did a second analysis of 
the same data using only PHOX2B and TH mRNA 
expression to deﬁ ne detectable samples (appendix).
Statistical analysis
Analyses were done by intention to treat. We targeted an 
enrolment of 486 patients, which would provide 80% 
power for a one-sided log-rank test of superiority of the 
purged group over the non-purged group at a level of 
0·05, able to detect a 9% improvement in 2-year event-
free survival (38% vs 47%). 
We did an intention-to-treat sequential monitoring of 
the trial, and considered early stopping if the groups 
proved19 or would never prove20 to be signiﬁ cantly diﬀ erent, 
or if the conditional power fell under 20%. We calculated 
the relative risk as the ratio of non-purged to purged using 
the planning variables for 2-year event-free survival, and 
under the alternative hypothesis, it would equal 1·33. The 
Fleming-Harrington-O’Brien20 lower (futility) boundary 
was equivalent to repeated testing of the alternative 
hypothesis at p=0·005 for a cumulative α level of 0·05. 
The total expected information was 341 events. Only the 
COG data safety monitoring committee and study 
statistician were aware of interim eﬃ  cacy monitoring 
results. Trial eﬃ  cacy results remained masked until 
release by the data safety monitoring committee after all 
patients had completed protocol therapy.
The primary endpoint was event-free survival, for 
which the time to event was calculated from study 
enrolment and randomisation until ﬁ rst occurrence of 
relapse, progressive disease, secondary malignancy, 
death, or until last contact with the patient if no event 
occurred. For overall survival, the time to event was 
calculated from study enrolment until death, or until last 
contact with the patient. Post-hoc, we also calculated 
event-free survival and overall survival from the time of 
transplant. We generated Kaplan-Meier survival curves.21 
We report 5-year point estimates with 95% CI.22
With the exception of the sequential monitoring, we 
deemed p values lower than 0·05 signiﬁ cant. We did the 
statistical analyses using SAS version 9.2 and Stata 
version 12.1. This trial is registered with ClinicalTrials.
gov, number NCT00004188.
Induction chemotherapy
Cycles: 1, 2, 4, 6 
Cyclophosphamide 
Doxorubicin 
Vincristine
2·1 g/m² per day intravenously × 2 days
25 mg/m² per day intravenously continuous infusion × 3 days
0·67 mg/m² per day intravenously continuous infusion × 3 days
Cycles: 3 and 5 
Cisplatin 
Etoposide
50 mg/m² per day intravenously × 4 days
200 mg/m² per day intravenously × 3 days
Consolidation chemotherapy AHSCT (CEM)
Melphalan
Carboplatin
Etoposide
G-CSF
70 mg/m² per day intravenously × 3 days 
425 mg/m² per day intravenously × 4 days (if GFR ≥100 mL/min per 1·73 m²)   
Adjust dose to AUC 4·1 per day using Calvert formula (if GFR <100 mL/min 
per 1·73 m²)   
338 mg/m² per day intravenously × 4 days (if GFR ≥100 mL/min per 1·73 m²) 
200 mg/m² per day intravenously × 4 days (if GFR <100 mL/min per 1·73 m²)  
5 μg/kg per day until ANC >2000 μL for 3 days
Radiation therapy
Fractionated radiotherapy (2160 cGy) given in 12 equal fractions of 180 cGy per fraction to 
primary site and to all MIBG avid metastatic sites at end induction beginning 30–45 days after
PBSC infusion 
Post-AHSCT therapy
Isotretinoin 80 mg/m² per dose orally twice a day × 14 days given every 28 days for six courses 
starting day 60
IsotretinoinRadiotherapyAHSCT1 2 3 4 5 6
Induction
PBSC harvest PBSC infusion at least 48 h after CEM
Consolidation
Figure 1: Treatment schema
PBSC=peripheral blood stem cells. AHSCT=autologous haemopoietic stem-cell transplantation. CEM=carboplatin, 
etopo side, and melphalan. GFR=glomerular ﬁ ltration rate. AUC=area under the curve. G-CSF=granulocyte 
colony-stimulating factor. ANC=absolute neutrophil count. MIBG=¹²³I or ¹³¹I- meta-iodobenzylguanidine.
See Online for appendix
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Role of the funding source
The NCI contributed to study design through scientiﬁ c 
review. Alex’s Lemonade Stand had no role in study 
design or reporting. Neither of these two funders had a 
role in data collection, data analysis, data interpretation, 
or writing of the report. All authors participated in 
writing the report and had full access to all the data in the 
study. The corresponding author had ﬁ nal responsibility 
for the decision to submit for publication.
Results
The trial ended after 495 patients had been enrolled 
(patients were enrolled from March 16, 2001, to Feb 24, 
2006). 486 patients were eligible for randomisation; 
243 were randomly assigned to receive purged PBSC and 
243 to receive non-purged PBSC (ﬁ gure 2). Baseline 
characteristics were much the same in each group and 
seemed similar to the COG overall high risk cohort 
(table 1).2 Median age of the patients was 3·1 years (range 
0·2–29·1 years). Of the 486 eligible for randomisation, 
137 (28%) patients subsequently enrolled in the COG 
ANBL0032 trial after transplantation, and 78 (16%) were 
assigned to the ch14.18 antibody group (36 of 243 in the 
purged group and 42 of 243 in the non-purged group).
We obtained PBSC from 465 (96%) of 486 randomised 
patients: 229 in the purged group and 236 in the non-
purged group. Transplantation was completed in 
372 patients (180 randomly assigned to purged and 192 to 
non-purged groups; ﬁ gure 2). Reasons patients were not 
transplanted included progressive disease (28 from 
purged group and 25 from non-purged group) or death 
during induction (eight from purged group and seven 
from non-purged group), organ toxic eﬀ ects (seven from 
purged group and ﬁ ve from non-purged group), 
withdrawal from protocol (three from purged group), 
insuﬃ  cient PBSC (ﬁ ve from purged group and one from 
non-purged group), insuﬃ  cient response (two from 
purged group and four from non-purged group), and 
other (ten from purged group and nine from non-purged 
group). 29 patients randomly assigned to purged PBSC 
could not comply because of insuﬃ  cient PBSC yield for 
purging (12 patients) or after purging (eight patients), 
regulatory or technical issues (six patients), positive 
microbial culture of PBSC (one patient), and parental 
refusal (two patients). Five (1%) of 439 patients with 
immunocytology from day 1 of leukapheresis before 
purging had detectable tumour (table 1). Four of these 
patients were randomly assigned to receive non-purged 
PBSC and underwent subsequent purged PBSC 
collection. The ﬁ fth patient, also assigned to receive non-
purged PBSC, had a negative sample from day 1 
immunocytology, but the pooled PBSC collection had 
positive immunocytology before purging. All ﬁ ve patients 
had negative immunocytology after purging.
For the whole study population, 5-year event-free 
survival from enrolment was 38% (95% CI 34–42) and 
5-year overall survival was 50% (95% CI 46–55), with 
243 allocated to non-purged 
         transplantation group
         187 received allocated intervention*
           56 did not receive allocated 
                  intervention
                  32 oﬀ study before transplantation 
                        for PD
                  19 oﬀ study before transplantation, 
                        other reason
                    5 crossover: infused with purged*
243 allocated to purged transplantation 
         group
         151 received allocated intervention* 
           92 did not receive allocated 
                  intervention
                  37 oﬀ study before transplant 
                        for PD†
                  26 oﬀ study before transplant, 
                         other reason
                  29 crossover: infused with 
                         non-purged PBSC or purged 
                         bone marrow*
0 lost to follow-up (intention-to-treat 
   analysis—all patients were included‡)
0 lost to follow-up (intention-to-treat 
    analysis—all patients were included‡)
243 analysed 243 analysed
495 patients assessed for eligibility, 
         enrolled, and randomised
9 excluded as ineligible
    3 ineligible stage 
    3 administrative issue 
    2 organ function not documented at study entry
    1 ineligible diagnosis
486 randomised
Figure 2: Trial proﬁ le
*372 patients (192 non-purged, 180 purged) received a transplant, including those who received the PBSC product to 
which they were allocated (randomised) and those who were crossovers. †One additional patient who received a 
transplant was retrospectively (post-transplant) determined by the treating institution to have had progressive 
disease at the end of induction; thus table 1 presents a total of 38 patients in the purged group with end of induction 
progressive disease. ‡Patients alive at last contact were censored in survival analysis.
Purged 
transplantation 
group (n=243)
Non-purged 
transplantation 
group (n=243)
Age 
<18 months 33/243 (14%) 31/243 (13%)
≥18 months 210/243 (86%) 212/243 (87%)
INSS stage at diagnosis
Stage 1* 2/243 (1%) 1/243 (0·4%)
Stage2a/2b 1/243 (<1%) 5/243 (2%)
Stage 3 29/243 (12%) 29/243 (12%)
Stage 4 208/243 (86%) 206/243 (85%)
Stage 4S 3/243 (1%) 2/243 (1%)
Tumour MYCN status
Ampliﬁ ed 85/194 (44%) 87/196 (44%)
Non-ampliﬁ ed 109/194 (56%) 109/196 (56%)
Unknown 49 47
Tumour histology
Favourable 7/171 (4%) 5/173 (3%)
Unfavourable 164/171 (96%) 168/173 (97%)
Unknown 72 70
(Continues on next page)
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median follow-up for patients without an event of 
6·2 years (IQR 5·2–7·8). Neither event-free survival nor 
overall survival from enrolment diﬀ ered between the 
purged and non-purged groups (ﬁ gure 3A, B). We also 
noted no diﬀ erence in event-free survival or overall 
survival from the time of transplantation between the 
purged and non-purged groups who completed 
transplantation (ﬁ gure 3C, D). Post-hoc analysis by 
treatment actually received showed no diﬀ erence in 
event-free survival (p=0·81) or overall survival (p=0·89) 
from study enrolment between groups; similar results 
were noted when event-free survival (p=0·15) and overall 
survival (p=0·23) were measured from time of 
transplantation (data not shown). In the 354 patients 
with stage 4 disease older than 18 months, event-free 
survival (p=0·32) or overall survival (p=0·77) from 
enrolment did not diﬀ er between the purged and non-
purged groups. Outcome was similar for individuals 
with protocol-deﬁ ned low compared with normal GFRs.
Although potentially underpowered and done post-hoc, 
analyses suggested that 5-year event-free and overall 
survival for the 270 patients with stage 4 disease with 
invaded bone marrow at diagnosis did not signiﬁ cantly 
diﬀ er between groups (p=0·20 for event-free survival and 
p=0·50 for overall survival). Similarly, for the 120 patients 
who were stage 4 with invaded bone marrow after two 
cycles of chemotherapy (at the time of PBSC collection), 
there was no diﬀ erence between groups in terms of 
5-year event-free or overall survival (p=0·22 for event-free 
survival and p=0·52 for overall survival). 
The 245 patients with TLDA results from day 1 of 
leukapheresis (before purging) were representative of all 
486 patients in terms of clinical and prognostic charac-
teristics (data not shown). Of these 245 patients, 
122 (50%) had detectable tumour mRNA by the ﬁ ve-gene 
TLDA: 68 (53%) of 129 patients in the purged group and 
54 (47%) of 116 patients in the non-purged group (table 1). 
Patients with detectable TLDA had lower event-free 
survival (at 5 years 29%, 95% CI 21–38) and overall 
survival (at 5 years 41%, 95% CI 32–50) than did patients 
with undetectable TLDA (5-year event-free survival 51%, 
95% CI 42–60; p=0·0003; and 5-year overall survival 
62%, 95% CI 53–70; p=0·0017; ﬁ gure 4). When we 
analysed the same data using only expression of TH and 
PHOX2B, 62 (25%) patients had detectable TLDA (34 in 
the purged group and 28 in the non-purged group), with 
lower event-free survival (at 5 years 26%, 95% CI 16–37) 
and overall survival (at 5 years 35%, 95% CI 23–47) than 
those with undetectable TLDA (5-year event-free survival 
45%, 95% CI 38–52; p=0·005; and 5-year overall survival 
58%, 95% CI 50–65; p=0·01). 60 (33%) of 183 PBSC with 
undetectable two-gene TLDA (PHOX2B and TH; 34 in 
the purged group and 26 in the non-purged group) were 
detectable using ﬁ ve genes.
Suﬃ  cient numbers of CD34 cells per protocol criteria 
were obtained in 443 of 465 patients: 221 of 229 in the 
purged group and 222 of 236 in the non-purged group. 
Purged 
transplantation 
group (n=243)
Non-purged 
transplantation 
group (n=243)
(Continued from preivous page)
Tumour ploidy
Hyperdiploid 84/189 (44%) 91/196 (46%)
Diploid 105/189 (56%) 105/196 (54%)
Unknown 54 47
Bone marrow morphology
After induction cycle 2
Negative 107/168 (64%) 118/177 (67%)
Positive 61/168 (36%) 59/177 (33%)
Unknown 75 66
At the end of induction
Negative 168/208 (81%) 181/216 (84%)
Positive 40/208 (19%) 35/216 (16%)
Unknown 35 27
PBSC day 1 immunocytology 
Positive 1/219 (<1%) 4/220 (2%)
Negative 218/219 (>99%) 216/220 (98%)
No harvest 14 7
Unknown day 1 immunocytology† 10 16
TLDA analysis of PBSC from day 1 of leukapheresis‡
Tumour detectable 68/129 (53%) 54/116 (47%)
Tumour undetectable 61/129 (47%) 62/116 (53%)
No TLDA specimen obtained or specimen of insuﬃ  cient quality 114 127
Overall response at the end of induction
Complete response 52/236 (22%) 55/241 (23%)
Very good partial response 62/236 (26%) 73/241 (30%)
Partial response 68/236 (29%) 65/241 (27%)
Stable disease 16/236 (7%) 16/241 (7%)
Progressive disease 38/236 (16%)§ 32/241 (13%)
Unknown 7 2
MIBG scan at the end of induction
Complete response 107/191 (56%) 100/197 (51%)
Less than complete response 84/191 (44%) 97/197 (49%)
Unknown 52 46
Transplantation
Number proceeding to stem-cell transplantation 180/243 (74%) 192/243 (79%)
Number for whom any stem-cell product infused was not the 
product randomised
35/180 (19%) 5/192 (3%)
Number for whom back-up PBSC infusion was given 5/180 (3%) 6/192 (3%)
Number receiving post-stem-cell transplantation anti-GD2 antibody 36/180 (20%) 42/192 (22%)
Post-induction GFR
≥100 mL/min per 1·73 m² (normal GFR) 163/194 (84%) 156/201 (78%)
<100 mL/min per 1·73 m² (low GFR) 31/194 (16%) 45/201 (22%)
Unknown 49 42
Proportions have been calculated excluding patients with unknown values. INSS=international neuroblastoma staging 
system. PBSC=peripheral blood stem cell. TLDA=TaqMan low density array. MIBG=meta-iodobenzylguanidine. 
GFR=glomerular ﬁ ltration rate. *Stage 1 at diagnosis and progressed to stage 4 without interval chemotherapy. †All 
but two patients without day 1 immunocytological data had immunocytology testing on a separate stem-cell sample 
before stem cell-infusion for transplantation; treating physicians chose to infuse non-immunocytology tested 
products in those two patients. ‡Percentages calculated on the basis of the number of patients who were harvested 
and who had a specimen of suﬃ  cient quality (129 purged, 116 non-purged, 245 overall). §One additional patient who 
received a transplant was retrospectively (post-transplant) determined by the treating institution to have had 
progressive disease at the end of induction.
Table 1: Patient characteristics 
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The median number of CD34 cells per kg infused was 
signiﬁ cantly greater for non-purged versus purged PBSC 
(5·6 [IQR 3·7–10·7] vs 3·7 [2·1–6·3] million; p<0·0001). 
Patients receiving non-purged PBSC had shorter median 
time to neutrophil engraftment (11 [IQR 10–12] vs 
12 [10–13] days; p=0·007) and platelet engraftment 
(19 [14–36] vs 28 [16–40] days; p=0·006) than did those 
receiving purged PBSC, with no evidence of a diﬀ erence 
in infection rates.
Five patients (three in the purged group, two in the 
non-purged group) required additional PBSC infusions 
for delayed neutrophil engraftment; all subsequently 
engrafted. Six patients (two in the purged group, four in 
the non-purged group) with initial neutrophil engraft-
ment received additional PBSC infusion because of 
secondary neutropenia or thrombocytopenia.
At the end of induction, 242 (51%) of 477 patients 
attained an overall complete response or very good partial 
response (table 1), 207 (53%) of 388 had a complete 
response by ¹³¹I or ¹²³I-meta-iodobenzylguanidine (MIBG) 
scan and 349 (82%) of 424 had no tumour detectable in 
bone marrow by standard morphology (table 1). 70 (15%) 
of 477 patients progressed during induction (table 1).
For brevity, the summary of toxic eﬀ ects (table 2) is 
limited to all protocol-required (targeted) toxic eﬀ ects 
and any non-haematological toxic eﬀ ects (non-targeted) 
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Figure 3: Event-free survival and overall survival
(A) Event-free survival for intention-to-treat population from time of enrolment or randomisation. (B) Overall survival for intention-to-treat population from time of enrolment or randomisation. 
(C) Event-free survival for comparison of patients randomly assigned to purged treatment group versus patients randomly assigned to non-purged treatment group, from time of transplantation. 
(D) Overall survival for comparison of patients randomly assigned to purged treatment group versus patients randomly assigned to non-purged treatment group, from time of transplantation.
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that occurred in 5% of patients or more. Ototoxic eﬀ ects 
requiring ampliﬁ cation (grade 3–4) occurred in 33 (7%) 
patients following induction (table 2). Systemic fungal 
infection during induction occurred in 40 (8%) of 
485 patients (18 in the purged group; 22 in the non-
purged group). There was no diﬀ erence in consolidation 
toxic eﬀ ects between the two randomised groups or the 
low versus normal GFR groups. 12 (7%) patients in the 
purged group and 17 (9%) of patients in the non-purged 
group had sinusoidal obstructive syndrome of grade 3 or 
higher. Sinusoidal obstructive syndrome was reported as 
severe in 15 (4%) patients (10 of 177 in the purged group, 
ﬁ ve of 191 in the non-purged group), life-threatening in 
13 (3%) patients (one of 177 in the purged group, 12 of 191 
in the non-purged group), or fatal in one (<1%) patient in 
the purged group.
The 15 (3%) deaths that occurred during induction 
were due to infection (four in the purged group and one 
in the non-purged group), tumour bleeding (three in 
the purged group and one in the non-purged group), 
tumour-related organ compromise (one in the purged 
group and two in the non-purged group), multi-organ 
failure (one death in non-purged group), unrelated 
event (one death in the non-purged group), and central 
venous line placement (one death in the purged group). 
Infectious deaths were from typhlitis (one death in the 
non-purged group), or fungal (two deaths in the purged 
group) and viral (two deaths in the purged group) 
causes. In the 12 (2%) deaths during consolidation 
(eight in the purged group and four in the non-purged 
group), causes included infection (three from 
adenovirus, one from cyto megalovirus, two from 
candida, one from aspergillus, and two bacterial 
infections), sinusoidal obstructive syndrome (one 
death), clinical sepsis with negative cultures (one death), 
and multi-organ failure (one death). In addition to the 
primary cause of death, ﬁ ve patients also had sinusoidal 
obstructive syndrome as a contributing factor in their 
death. 
Discussion
To our knowledge, this is the only randomised study of 
tumour-selective PBSC purging in any cancer (panel). 
Similar outcomes for the purged and non-purged groups 
establish that non-purged PBSC are acceptable for 
support of myeloablative therapy of high-risk neuro-
blastoma. Despite not requiring morphologically 
tumour-negative bone marrow before PBSC collection, 
only 1% of PBSC samples had tumour detectable by 
immunocytology; therefore, immunocytological testing 
of PBSC has been eliminated in COG studies.
The proportion of patients who achieved complete or 
very good partial response following induction 
chemotherapy in this trial was 51%, similar to other 
groups24,25 compared with 87·5% as originally reported 
(with small patient cohort at one institution).26 Response 
and progressive disease rates were similar to the less 
intensive CCG 3891 induction, which had fewer 
induction deaths.2
This trial escalated carboplatin, etoposide, and 
melphalan doses from the CCG 3891 regimen and 
omitted total body radiation (TBI), while maintaining a 
5-year event-free survival similar to that reported in the 
myeloablative chemotherapy plus isotretinoin group 
from CCG 3891.2 TBI was replaced with irradiation to the 
primary tumour site and post-induction MIBG avid 
metastatic sites. TBI is associated with short stature, 
cataracts, dental abnormalities, thyroid dysfunction, and 
radiation pneumonitis.27 The toxic eﬀ ects from the 
escalated chemotherapy regimen were tolerable, with 
Figure 4: Event-free survival and overall survival by TLDA test results
(A) Event-free survival. (B) Overall survival. TLDA=TaqMan low density array. PBSC=peripheral blood stem cells. 
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sinusoidal obstructive syndrome of grade 3 or higher 
occurring in roughly the same proportion of patients as 
with the CCG 3891 CEM-TBI regimen,2 where it led to 
death in 3% of patients. Similar results were obtained in 
a pilot study of tandem high dose chemotherapy using 
cyclophosphamide and thiotepa followed by CEM with 
PBSC rescue.12
Immunomagnetic purging of PBSC did not improve 
outcome, possibly because of incomplete purging or due 
to residual tumour in patients. In preclinical modelling, 
immunomagnetic purging removed 3–4 logs of tumour 
cells from bone marrow when starting with 10–20% 
tumour cells.16 All ﬁ ve PBSC products with tumour 
detected by immunocytology from the sample of day 1 
became undetectable after purging, which supports a 
purging eﬀ ect. The number of randomised patients 
achieving complete response were insuﬃ  cient to resolve 
the issue of whether residual tumour in patients was a 
possible cause for the failure of purging to improve 
outcome. All patients received isotretinoin and similar 
numbers of patients from both groups received post-
consolidation ch14.18 antibody plus cytokines. This post-
consolidation therapy might have eliminated tumour 
cells infused in the stem-cell product, which could 
obscure an eﬀ ect of purging.
Apheresis was planned after cycle two of induction to 
obtain adequate CD34 cell per kg yield and avoid stem-
cell exposure to topoisomerases to decrease secondary 
leukaemia risk.26 Results from a previous study5 showed a 
very low incidence of immunocytology-detectable 
tumour in PBSC even when bone marrow contained 
residual neuroblastoma at the time of pheresis.5 This 
result was conﬁ rmed in our current study, with only 
1·2% of PBSC products having immunocytology-
detectable tumour.
We assessed TLDA on an aliquot of PBSC from day 1 of 
leukapheresis to assess the prognostic signiﬁ cance of 
TLDA before any manipulation of PBSC for all patients. 
Purged transplantation group* Non-purged transplantation group*
Grade 1–2 Grade 3 Grade 4 Grade 5 Grade 1–2 Grade 3 Grade 4 Grade 5
Induction†
Targeted toxic eﬀ ects‡ 
Hearing loss 70/242 (29%) 16/242 (7%) 0 0 75/243 (31%) 17/243 (7%) 0 0
Cardiac left ventricular function 13/242 (5%) 3/242 (1%) 1/242 (<1%) 0 14/243 (6%) 3/243 (1%) 2/243 (1%) 0
Stomatitis/pharyngitis 80/242 (33%) 50/242 (21%) 37/242 (15%) 0 81/243 (33%) 52/243 (21%) 41/243 (17%) 0
Serum creatinine 18/242 (7%) 4/242 (2%) 0 1/242 (<1%) 20/243 (8%) 5/243 (2%) 1/243 (<1%) 0
Non-targeted toxic eﬀ ects§
Infection or febrile neutropenia: catheter related infection 0 32/242 (13%) 4/242 (2%) 0 1/243 (<1%) 28/243 (12%) 6/243 (2%) 0
Consolidation¶
Targeted toxic eﬀ ects
Acute vascular leak 6/177 (3%) 7/177 (4%) 4/177 (2%) 0 5/191 (3%) 5/191 (3%) 4/191 (2%) 0
Cardiac left ventricular function 11/177 (6%) 1/177 (<1%) 0 0 5/191 (3%) 2/191 (1%) 2/191 (1%) 0
Weight gain 7/177 (4%) 9/177 (5%) 1/177 (<1%) 0 9/191 (5%) 4/191 (2%) 12/191 (6%) 0
Stomatitis or pharyngitis 28/177 (16%) 94/177 (53%) 37/177 (21%) 0 30/191 (16%) 104/191 (54%) 40/191 (21%) 1/191 (<1%)
Bilirubin 34/177 (19%) 16/177 (9%) 4/177 (2%) 0 35/191 (18%) 15/191 (8%) 6/191 (3%) 0
Hepatic enlargement 0 31/177 (18%) 0 0 0 28/191 (15%) 0 0
Stem-cell infusion complications 19/177 (11%) 7/177 (4%) 1/177 (<1%) 0 18/191 (9%) 7/191 (4%) 2/191 (1%) 0
Sinusoidal obstruction syndrome 11/177 (6%) 10/177 (6%) 1/177 (<1%) 1 (<1%) 16/191 (8%) 5/191 (3%) 12/191 (6%) 0
Serum creatinine 8/177 (5%) 2/177 (1%) 0 0 13/191 (7%) 2/191 (1%) 1/191 (<1%) 0
Non-targeted toxic eﬀ ects
Renal failure 0 1/177 (<1%) 1/177 (<1%) 0 0 8/191 (4%) 3/191 (2%) 0
Infection or febrile neutropenia: catheter-related infection 0 13/177 (7%) 0 0 0 15/191 (8%) 2/191 (1%) 0
Isotretinoin||
Targeted toxic eﬀ ects
Hypertension 5/98 (5%) 1/98 (1%) 0 0 3/94 (3%) 3/94 (3%) 0 0
Haematuria 14/98 (14%) 0 0 0 15/94 (16%) 1/94 (1%) 1/94 (1%) 0
Serum creatinine 10/98 (10%) 1/98 (1%) 0 0 12/94 (13%) 0 1/94 (1%) 0
Proteinuria 7/98 (7%) 1/98 (1%) 0 0 14/94 (15%) 1/94 (1%) 1/94 (1%) 0
*A given patient is counted once for a given toxicity at the highest grade within a treatment period. †One patient in the purged transplantation group died on day of enrolment, never received any treatment, 
and was therefore excluded from toxicity analysis. ‡Targeted toxic eﬀ ects: selected organ or infectious toxic eﬀ ects with mandatory reporting of all grades. §Non-targeted toxic eﬀ ects: required reporting of all 
grade 3–5 toxic eﬀ ects. ¶Data were not reported regarding toxicity for three patients in the purged transplantation group and one patient in the non-purged transplantation group. ||There were no non-targeted 
toxic effects of grades 3–5 that were noted in more than 5% of patients. 
Table 2: Summary of protocol-required targeted toxic eﬀ ects, and non-hematological toxic eﬀ ects that occurred in 5% of patients or more 
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Our analysis showed a detectable signal by ﬁ ve-gene 
TLDA was associated with a worse outcome. We did an 
additional analysis of our TLDA data using only TH and 
PHOX2B expression to compare with other studies.6–8 
Our patients with a detectable signal with either TH or 
PHOX2B also had signiﬁ cantly worse outcome compared 
with those patients with an undetectable signal. A higher 
number of patients had a detectable signal with the ﬁ ve-
gene than with the two-gene analysis, providing more 
sensitive or less speciﬁ c, or both, tumour mRNA 
detection. Thus, TLDA analysis of PBSC provides novel 
prognostic information that might provide early 
identiﬁ cation of patients requiring alternative therapy. 
Smaller series have shown conﬂ icting results regarding 
the prognostic value of minimum tumour detection in 
PBSC.6–8 Data from other groups support the prognostic 
signiﬁ cance of QrtPCR detection of neuroblastoma 
mRNA in bone marrow.28,29 An international task force is 
currently assessing QrtPCR methodologies to reach a 
consensus for implementing this technology.30 
Multivariable analysis of signiﬁ cance of TLDA compared 
with other prognostic factors is ongoing. Further analyses 
that are still in progress include the detection of tumour 
mRNA by ﬁ ve-gene TLDA in bone marrow and peripheral 
blood and multivariate analysis of TLDA, MIBG score, 
bone marrow morphology, and overall clinical response.
The study was designed to assess the eﬀ ect of purging 
in patients with high-risk neuroblastoma as deﬁ ned by 
the COG. It was not powered to assess outcome in the 
subset of patients with stage 4 disease aged 18 months or 
older. However, because of the insuﬃ  cient evidence for 
an outcome diﬀ erence in the treatment groups, this 
limitation became a non-issue. Another potential 
limitation is the lack of data from TLDA analyses before 
and after purging. Although we measured this in a subset 
of patients, the purging methodology might have caused 
technical interference with interpretation of the TLDA 
assay, which would prevent accurate quantiﬁ cation of the 
tumour mRNA reduction after purging. As such, we 
have not presented these data. 
In conclusion, our results support the use of non-
purged PBSC products following myeloablative therapy 
of high-risk neuroblastoma.
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